Approved indications (U.S.): Dasatinib is approved for adults with newly diagnosed Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP); adults with chronic, accelerated, or blast phase Ph+ CML resistant or intolerant to prior therapy including imatinib; adults with Ph+ acute lymphoblastic leukemia (Ph+ ALL) resistant or intolerant to prior therapy; and pediatric patients (≥1 year) with Ph+ CML in chronic phase or Ph+ ALL in combination with chemotherapy.

Off-label uses: Clinicians sometimes use dasatinib off-label for other BCR-ABL–positive leukemias or for patients after stem cell transplant with minimal residual disease; evidence is generally from small trials and cohort studies rather than large randomized phase 3 trials.

Efficacy expectations: In Ph+ CML-CP, many patients achieve complete hematologic response within weeks and deep cytogenetic or molecular responses over months to years, with long-term disease control comparable to other second-generation tyrosine kinase inhibitors; in advanced CML and Ph+ ALL, responses are typically faster but remission durations may be shorter and often used as a bridge to other therapies such as stem cell transplant.

Comparison to similar drugs: Compared with imatinib, dasatinib generally produces faster and deeper molecular responses in newly diagnosed CML but has different side-effect patterns (for example, more pleural effusions); relative to other second-generation TKIs (nilotinib, bosutinib), efficacy is broadly similar, and drug choice often depends on side-effect profile, comorbidities, and potential drug interactions.

Typical adult dosing: For newly diagnosed Ph+ CML in chronic phase, the usual dose is 100 mg by mouth once daily; for accelerated or blast phase CML and for Ph+ ALL, the usual dose is 140 mg once daily. Some patients may require dose reductions or interruptions based on side effects or blood counts.

Pediatric dosing: In children with Ph+ CML-CP or Ph+ ALL (with chemotherapy), dosing is typically based on body weight or body surface area, given once daily, with maximum daily dose limits; exact dosing is determined by the treating specialist.

How to take: Swallow tablets whole with water; do not crush, cut, or chew. Dasatinib can be taken with or without food, ideally at the same time each day. Avoid taking it with grapefruit or grapefruit juice because this can increase drug levels.

Special instructions: Dose adjustments may be needed for strong interactions (for example, with certain antifungals or antibiotics) or if significant side effects occur. Treatment is usually continuous as long as it is effective and tolerated, although in some patients with deep and sustained molecular responses, specialists may consider carefully monitored treatment discontinuation protocols.

Missed dose: If a dose is missed and it is close to the time of the next dose, skip the missed dose and take the next dose at the regular time; do not take two doses at once to make up for a missed dose.

Overdose: In case of suspected overdose, contact emergency medical services or a poison control center immediately; there is no specific antidote, so management focuses on monitoring and treating symptoms and complications such as severe low blood counts or heart rhythm changes.

Common side effects: Frequently reported effects include low blood counts (anemia, neutropenia, thrombocytopenia), headache, fatigue, nausea, diarrhea, fluid retention (including swelling around the eyes, hands, or feet), skin rash, and muscle or bone pain. These often begin in the first weeks to months of therapy and are usually mild to moderate but can occasionally be severe, especially low blood counts.

Serious or rare adverse effects: Important risks include pleural effusion (fluid around the lungs causing shortness of breath or cough), pulmonary arterial hypertension, severe myelosuppression with infections or bleeding, severe bleeding events, heart rhythm changes (QT prolongation), congestive heart failure, arterial or venous thrombosis, tumor lysis syndrome, and liver injury. Sudden shortness of breath, chest pain, coughing up blood, severe dizziness or fainting, rapid weight gain, or signs of infection or bleeding require urgent medical attention.

Warnings and precautions: Use in pregnancy can harm the unborn baby; effective contraception is recommended during treatment and for a period after the last dose. Breastfeeding is generally not recommended while taking dasatinib. Caution and dose adjustments may be needed in patients with liver impairment; careful monitoring is advised in patients with heart disease, lung disease, or a history of pleural effusion, bleeding disorders, or uncontrolled hypertension.

Relative safety compared with other TKIs: Overall safety is similar to other second-generation BCR-ABL inhibitors but with a higher tendency toward pleural effusions and certain fluid-retention events; some alternative TKIs may be preferred in patients at high risk for lung or pleural problems, while dasatinib may be favored when other TKIs are poorly tolerated or ineffective.

Side-effect reporting and safety updates: Patients and caregivers can report suspected side effects to a healthcare professional, to the FDA’s MedWatch reporting program, or to the drug manufacturer; updated safety information is available through these channels and in the prescribing information.

Drug interactions: Dasatinib is metabolized mainly by CYP3A4, so strong CYP3A4 inhibitors (such as certain azole antifungals, macrolide antibiotics, and some antivirals) can raise dasatinib levels and increase toxicity, while strong CYP3A4 inducers (such as rifampin, carbamazepine, phenytoin, and St. John’s wort) can lower levels and reduce effectiveness. It may interact with drugs that prolong the QT interval (for example, some antiarrhythmics, antipsychotics, and fluoroquinolone antibiotics) and with anticoagulants or antiplatelet agents, which can increase bleeding risk.

OTC medicines, supplements, and foods: Antacids, H2 blockers, and proton pump inhibitors can reduce dasatinib absorption by raising stomach pH; antacids should be separated by at least 2 hours before or after dasatinib, and chronic PPIs or H2 blockers are generally discouraged if avoidable. Grapefruit or grapefruit juice can increase dasatinib levels and should be avoided. Herbal supplements that affect CYP3A4 (especially St. John’s wort) should not be used unless cleared by the prescriber.

Alcohol and procedures: Moderate alcohol intake may further stress the liver or worsen dizziness or fatigue and is usually limited or avoided based on the patient’s overall health. Before surgery or invasive procedures, clinicians may adjust or temporarily stop dasatinib due to risks of bleeding and low blood counts.

Precautions and contraindications: Use with caution in patients with significant heart disease, history of arrhythmias or QT prolongation, uncontrolled hypertension, prior pleural effusions or lung disease, active bleeding disorders, or moderate to severe liver impairment. Baseline and periodic evaluations are recommended to assess organ function and manage risks.

Monitoring needs: Regular complete blood counts are needed, especially during the first months, to detect low blood cell counts. Liver function tests and, in some patients, kidney function and electrolytes are monitored periodically. An ECG may be obtained at baseline and as needed to check the QT interval, particularly when other QT-prolonging drugs are used. Clinical monitoring for signs of pleural effusion, fluid retention, shortness of breath, chest pain, or sudden weight gain is important throughout treatment.

Q: How long will I need to stay on dasatinib?
A: Many people with chronic-phase CML take dasatinib for years as a long-term treatment; in selected patients with very deep, stable molecular responses, specialists may consider carefully monitored treatment discontinuation, but this decision is individualized.

Q: When should I expect to see results from dasatinib?
A: Blood counts often improve within a few weeks, while deeper responses seen on chromosome or molecular tests usually develop over several months and continue to deepen over time.

Q: Can I take antacids or heartburn medicine with dasatinib?
A: Short-acting antacids may be used if they are taken at least 2 hours before or after dasatinib, but long-term use of proton pump inhibitors or H2 blockers should generally be avoided or carefully managed because they can reduce how well dasatinib is absorbed.

Q: What should I do if I become pregnant or want to become pregnant while on dasatinib?
A: Dasatinib can harm an unborn baby, so effective birth control is recommended; if pregnancy occurs or is planned, contact your oncology team promptly to discuss risks and alternative treatment options.

Q: Is it safe to get vaccines while taking dasatinib?
A: Inactivated (non-live) vaccines are generally permitted and often recommended, but live vaccines may be unsafe because of weakened immunity; always check with your oncology team before receiving any vaccine.

Storage: Store dasatinib tablets at room temperature (generally 68°F–77°F / 20°C–25°C), in the original container, tightly closed, and protected from moisture; keep out of reach of children and pets.

Handling: Do not crush, cut, or chew tablets; caregivers should avoid touching broken tablets and wash hands after handling.

Disposal: Do not flush unused tablets down the toilet or throw them in household trash; use a medicine take-back program when available or follow pharmacist or local waste authority instructions for safe disposal.